Key Drivers
- Strong Margins
- Higher Leverage
- Rich Valuation
AIAI Summary
BMRN has shifted from a stable rare-disease cash generator to a leveraged growth story, so the investment now hinges on management sustaining 20% revenue growth from VOXZOGO and acquisitions while rapidly deleveraging—if execution slips, rising interest expense and integration costs will cap EPS upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Higher Leverage
- •Rich Valuation
BMRN remains highly profitable and cash-generative, but rising debt, higher interest expense, and a weaker balance sheet have increased risk while the stock still looks expensive.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Momentum cooled
- •Layered support
BMRN has turned from a choppy base into a strong uptrend over the last month, but after a fast breakout above $60 and a push to $70.24 it is now extended and must hold $63.8 to keep the bullish setup intact.
Fast rally from the high-$50s to $70.24 raises short-term pullback risk
Sentiment & News
Key News Insights:
- •Revenue outperformance
- •Guidance raised
- •Portfolio expansion
BioMarin posted strong Q2 results and raised 2026 guidance, with VOXZOGO and rare-disease growth, portfolio expansion, and commercial execution supporting a more constructive long-term outlook.
The news is likely supportive for BioMarin's shares as it reinforces accelerating growth, better execution, and improving margin potential
Similar Companies in Healthcare
Other companies in the same sector with AI ratings